Financial Data and Key Metrics Changes - In Q1 2025, Tarsus Pharmaceuticals generated over $78 million in Xtendi sales, a year-over-year increase of 217%, driven by approximately 72,000 bottles dispensed to patients [4][20] - The gross to net discount was approximately 47%, reflecting strong coverage and an adjustment to Medicare accrual estimates [20][21] - Total operating expenses were approximately $104.6 million, an increase of $14 million compared to Q4 2024, primarily due to direct-to-consumer advertising and related marketing costs [21][22] - The company ended the quarter with approximately $407.9 million in cash and cash equivalents, bolstered by a recent equity raise of approximately $135 million [23] Business Line Data and Key Metrics Changes - Xtendi's sales growth was driven by an expanded sales force and increased prescribing frequency among eye care professionals (ECPs), with a 110% increase in ECPs writing more than one prescription per week compared to Q3 2024 [13][14] - The company anticipates dispensing between 85,000 to 90,000 bottles in Q2 2025, with a gross to net discount expected in the range of 45% to 47% [25] Market Data and Key Metrics Changes - The company reported that over 90% of commercial and Medicare lives are covered, significantly reducing barriers to physician adoption [15][20] - The DTC campaign has led to a 140% increase in average weekly website visits in March 2025 compared to December 2024 [15][18] Company Strategy and Development Direction - Tarsus aims to establish itself as a leader in eye care by creating new categories of treatment, with a focus on Xtendi and the upcoming Xembi launch [4][11] - The company is exploring global opportunities for Xtendi, particularly in Japan and Europe, with potential regulatory approval in Europe expected by 2027 [7][8] - Tarsus is also advancing its pipeline with TPO4 for ocular rosacea, targeting a significant and underserved market [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Xtendi, citing strong sales force performance and effective DTC campaigns as key drivers [19][26] - The company anticipates continued revenue growth, despite potential headwinds in Q3 due to seasonal factors, with stronger growth expected in Q4 [25][26] Other Important Information - The company has a proven blueprint for success and is well-positioned for sustained revenue growth in the coming years [11][26] - Management highlighted the importance of patient education and awareness as critical components of their growth strategy [78] Q&A Session Summary Question: Have there been any disruptions in meeting with the FDA regarding pipeline products? - Management confirmed there have been no delays in meeting schedules and they are on track to start trials in the second half of the year [30][31] Question: What is the current split between Medicare and commercial prescriptions? - The script volume is currently split relatively equally between Medicare and commercial prescriptions, with Medicare coverage acting as a significant growth driver [33][34] Question: What are the key drivers for repeat prescribing? - Key drivers include an expanded sales force and improved coverage, which have led to increased frequency of prescribing among doctors [38][40] Question: How is the feedback from the ORION Registry and MGD data being received? - Doctors are responding positively to the new data, which is prompting them to diagnose more patients and consider a broader range of conditions [54] Question: What are the potential factors affecting future guidance? - Factors include the impact of the DTC campaign and macroeconomic events, which may affect visibility for long-range guidance [63] Question: What is the expected level of stocking in the channel? - The company does not anticipate changes in stocking levels, which have remained consistent at around two to two and a half weeks [66]

Penske Automotive Group (PAG) Q1 2025 Earnings Call April 30, 2025 02:00 PM ET Company Participants Tony Pordon - Executive Vice President Investor Relations and Corporate Business DevelopmentRoger Penske - Chairman & CEORichard Shearing - Chief Operating Officer of North American OperationsRandall Seymore - Chief Operating Officer of International OperationsShelley Hulgrave - Executive Vice President & CFOJohn Murphy - Managing DirectorDaniela Haigian - Vice President - Equity ResearchRon Jewsikow - Direct ...

The Vita Coco Company (COCO) Q1 2025 Earnings Call April 30, 2025 08:30 AM ET Speaker0 Good day, and welcome to the Vitacoco Company First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. After the speaker presentation, there will be a question and answer session. To withdraw your question, press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker, Mr. John Mills, managing ...

Centene Corporation (NYSE:CNC) Q1 2025 Earnings Conference Call April 25, 2025 8:30 AM ET Company Participants Jennifer Gilligan - Senior Vice President, Finance and Investor Relations Sarah London - Chief Executive Officer Andrew Asher - Executive Vice President and Chief Financial Officer Conference Call Participants Josh Raskin - Nefron Research A.J. Rice - UBS Justin Lake - Wolfe Research Ann Hynes - Mizuho Securities Stephen Baxter - Wells Fargo David Windley - Jefferies Sarah James - Cantor Fitzgerald ...

Group 1: Meeting Overview - The CEOs of Walmart and Target met with President Trump to discuss trade negotiations and the impact of tariffs on imported products [1][2] - Walmart CEO Doug McMillon described the meeting as "productive" and highlighted discussions on tariffs and their effects on the retail industry [2][3] - Target CEO Brian Cornell also found the meeting productive, focusing on a "path forward on trade" [5] Group 2: Trade Negotiations and Tariffs - Trump is negotiating with 75 countries for bilateral trade deals during a 90-day pause on his tariff plan, with 15 countries currently in active negotiations [8] - All nations that have not retaliated against the U.S. will face a 10% tariff, while tariffs on Chinese imports have been increased to 145%, leading to a 125% duty on American goods from China [9] Group 3: Industry Impact - The National Retail Federation warns that Trump's tariffs would drive up consumer prices, indicating potential challenges for the retail sector [8] - Home Depot CEO Ted Decker attended the meeting, while Lowe's CEO Marvin Ellison was absent, suggesting varying levels of engagement among major retailers [7]

Marsh & McLennan Companies, Inc. (MMC) Q1 2025 Earnings Conference Call April 17, 2025 08:30 AM ET Company Participants Operator - Conference Call OperatorJohn Doyle - President and CEO, Marsh McLennanMark McGivney - CFO, Marsh McLennanMartin South - CEO, MarshDean Klasura - CEO, Guy CarpenterNick Studer - CEO, Oliver Wyman Conference Call Participants Mike Zaremski - Analyst, BMO Capital MarketsJimmy Buehler - Analyst, J.P. MorganDavid Motomaden - Analyst, Evercore ISIAlex Scott - Analyst, BarclaysMayor Sh ...

The Expansion Brings New 270-Degree Panoramic Auditoriums to Shakopee, MN, Columbus, OH and The First-Ever SCREENX in Illinois HOLLYWOOD, Calif., April 2, 2025 /PRNewswire/ -- CJ 4DPLEX, the world's leading producer of premium film formats and cinema technologies, and Marcus Theatres®, a division of Marcus Corporation (NYSE: MCS) and the fourth largest exhibitor in the U.S., announced today an expansion of their successful partnership with the addition of three new 270-degree panoramic SCREENX auditoriums i ...

Dolby Laboratories, Inc. (DLB) recently deepened its collaboration with AMC Entertainment (AMC) . After a decade of success and strong guest demand, the two entertainment bigshots plan to expand by adding 40 more Dolby Cinema locations at AMC theaters across the United States by the end of 2027. This roughly 25% increase will bring the total number of Dolby Cinema at AMC auditoriums to more than 200 locations nationwide. Dolby Cinema is DLB's premier theatrical solution, designed for both exhibitors and mov ...

Keurig Dr Pepper (KDP) Q3 2024 Earnings Call October 24, 2024 08:00 AM ET Company Participants Jane Gelfand - Vice President of Investor Relations & Strategic InitiativesTim Cofer - CEOSudhanshu Priyadarshi - CFO & President of InternationalKaumil Gajrawala - Managing DirectorBrett Cooper - Managing PartnerDara Mohsenian - Managing Director - US Beverage/Household Products SectorsRobert Ottenstein - Senior Managing Director & Partner Conference Call Participants Christopher Carey - Equity Analyst - Head of ...